AnX Robotica Cites FDA Data Showing 88.6% Reduction in Capsule Review Time

The comparison stems from recent FDA filings, specifically the September 2026 clearance of a competitor that utilized AnX Robotica’s NaviCam ProScan as its primary predicate device. While both platforms aim to streamline clinician review of capsule endoscopy studies, the clinical data underscores a substantial gap in efficiency. In the prospective multicenter ARTIC study, ProScan reduced average reading times from 33 minutes and 42 seconds to just 3 minutes and 50 seconds. Conversely, the recently cleared comparator reduced review times from 45.7 minutes to 34.4 minutes.

Tim Thomas, Vice President of Regulatory and Clinical Affairs at AnX Robotica, emphasized that these figures reflect distinct study designs, patient populations, and validation datasets rather than a direct head-to-head trial. Despite the variance in results, both companies maintain that their respective AI tools are designed to support, not replace, the physician’s final interpretation. The FDA regulatory summaries reinforce this distinction, noting that clinicians remain responsible for all diagnostic assessments while using these automated aids.